{"url_path":"/sec/inbx/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000027-index.html","accession_number":"0002007919-26-000027","cik":"0002007919","ticker":"INBX","issuer_name":"Inhibrx Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000027-index.html","primary_entity_key":"0002007919","primary_entity_name":"Inhibrx Biosciences, Inc."},"word_count":456,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n(a) Exhibits.\n\nExhibit No.\nDescription of Exhibit\nFiled Herewith\nFormIncorporated By Reference File No.Date Filed\n\n3.1\n\n[Amended & Restated Certificate of Incorporation of Inhibrx Biosciences, Inc.](https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/tm243190d19_ex3-1.htm)\n\n8-K\n\n001-42031\n5/30/2024\n\n3.2\n\n[Amended & Restated Bylaws of Inhibrx Biosciences, Inc.](https://www.sec.gov/Archives/edgar/data/2007919/000110465924066645/tm243190d19_ex3-2.htm)\n\n8-K\n\n001-42031\n5/30/2024\n\n4.1\n\n[Form of Warrant to Purchase Stock](https://www.sec.gov/Archives/edgar/data/2007919/000110465924051494/tm243190d7_ex4-1.htm)\n10\n001-42031\n4/25/2024\n\n4.2\n[Form of Warrant to Purchase Stock by and between Inhibrx Biosciences, Inc. and entities affiliated with Oxford Finance LLC](exhibit42-formofwarrantoxf.htm)\n\nX\n\n10.1\n\n[First Amendment to the Loan and Security Agreement, dated March 18, 2026, among Inhibrx Biosciences, Inc., Oxford Finance LLC, and the other lenders party thereto](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/exhibit1012-oxfordfirstame.htm)\n10-K001-420313/19/2026\n\n31.1\n[Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](exhibit311q12026.htm)\nX\n\n31.2\n[Certification of Principal Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](exhibit312q12026.htm)\nX\n\n32.1*\n[Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](exhibit321q12026.htm)\nX\n\n32.2*\n[Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](exhibit322q12026.htm)\nX\n\n101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL documentX\n\n101.SCHInline XBRL Taxonomy Extension Schema DocumentX\n\n101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase DocumentX\n\n101.DEF Inline XBRL Taxonomy Extension Definition Linkbase DocumentX\n\n101.LAB Inline XBRL Taxonomy Extension Label Linkbase DocumentX\n\n101.PREInline XBRL Taxonomy Extension Presentation Linkbase DocumentX\n\n104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document contained in Exhibit 101X\n\n^ Certain exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally to the SEC a copy of any omitted exhibits or schedules upon request. Pursuant to Item 601(a)(6) of Regulation S-K, certain information from this exhibit have been redacted as their disclosure would constitute a clearly unwarranted invasion of personal privacy.\n\n*    This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.\n\n32\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nINHIBRX BIOSCIENCES, INC.\n\nDate: May 14, 2026\n/s/ Mark P. Lappe\n\nMark P. Lappe\n\nChief Executive Officer and Chairman\n\n(Principal Executive Officer)\n\nDate: May 14, 2026\n/s/ Kelly D. Deck\n\nKelly D. Deck, C.P.A.\n\nChief Financial Officer\n\n(Principal Financial and Accounting Officer)\n\n33"}